Rely-V® is an innovative IV drug flow monitoring technology, currently in development for neonatal and pediatric intensive care applications
We are working hard to develop the Rely-V® technology into a trustworthy platform that can enhance neonatal and pediatric patient care. As we navigate this dynamic market and tackle regulatory challenges, we recognize the invaluable role that partners and investors can play in realizing our vision.
We are actively fund-raising for our seed investment round to enable us to advance the development of Rely-V®. Please reach out to us for further information and investment opportunities!
We are actively fund-raising for our seed investment round to enable us to launch the Rely-V™ research-use device on the market by 2026. Please reach out to us for further information and investment opportunities!
The Rely-V™ is currently in the validation phase, we are searching for institutes that would be interested in testing the product and work with us to improve and optimize the opportunities.
Sencilia, founded in September 2021, spun out from the University of Groningen with the mission to enhance the safety of IV infusion therapy for vulnerable patients. Our innovative flow sensor technology is being developed in collaboration with renowned partners such as Erasmus Medical Center and the University Medical Center Groningen. We are currently developing Rely-V® technology, with the vision of becoming the standard of care in IV infusion therapy by 2030.
IMPORTANT NOTICE: Rely-V® is an investigational technology currently under development and pre-clinical evaluation. It is not a certified medical device, not CE-marked or FDA-approved, and not available for clinical use or sale. The technology may not be used in any clinical setting. All descriptions reflect our development objectives and are subject to regulatory approval and clinical validation. The information presented is intended for research partners, potential investors, and other interested parties only.
